(New York) The Perrigo lab announced Monday that it had asked American authorities for the green light for the first over-the-counter contraceptive pill in the United States, a few weeks after the Supreme Court’s decision to revoke the right to abortion in the United States Country.
Posted at 12:46 p.m
It is a French subsidiary of the pharmaceutical group HRA Pharma, which submitted a dossier to the American Medicines Agency (FDA) for Opill, a daily pill based on a synthetic progestin, without estrogen, which has been available on prescription since 1973 , describes a press release.
The initiation of regulatory proceedings shortly after the Supreme Court’s June 24 decision to overturn abortion rights nationwide is “a coincidence,” the company says, noting that the HRA has been working on the case for seven years have years.
The FDA declined to comment.
“This historic trial marks a turning point in contraceptive access and reproductive equity in the United States,” commented Frédérique Welgryn, director of strategic operations and innovation at HRA Pharma, in the press release.
If given the green light, it will “help even more women and people gain access to contraception without unnecessary barriers,” she added.
Birth control pills are already available over the counter in many countries, including Brazil, Mexico, Portugal and Turkey. Other countries prefer to require a doctor’s visit, especially to avoid possible contraindications and to discuss the risks for blood pressure.
However, several major medical organizations in the US, including the Council of Obstetricians and Gynecologists (ACOG), have already expressed support for over-the-counter pills.
“The data confirm that progestogen-only hormone methods are generally safe and pose no or minimal risk of venous thromboembolism,” ACOG said in a post on its website.
“Several studies have shown that women are able to self-test to determine if they are eligible to use hormonal contraceptives,” the organization adds.